Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Are We Approaching the End of Antibiotic Therapy?

By LabMedica International staff writers
Posted on 23 Aug 2010
The emergence of a new antibiotic resistance mechanism in India, Pakistan, and the United Kingdom represents a potentially major global health problem, and possibly signals the end of effective antibiotics treatments, according to a new study. More...


Researchers at the University of Madras (Chennai, India), Cardiff University (United Kingdom), and other institutions investigated the prevalence of carbapenem resistant gram-negative Enterobacteriaceae conferred by the New Delhi metallo-beta-lactamase 1 (NDM-1) resistance gene; the multidrug-resistant bacteria is found in India, Pakistan, and the U.K. The researchers isolated the bacteria from two major population centers in India--Chennai (in south India), and Haryana (in northern India)--and referred them to the U.K. National Reference Laboratory (NRL; Weymouth). Antibiotic susceptibilities were assessed, and the presence of the NDM-1 resistance gene was established by polymerase chain reaction (PCR). Isolates were typed by electrophoresis of genomic DNA, and plasmids were analyzed by S1 nuclease digestion and PCR typing. The researchers also reviewed case data regarding the UK patients to look for evidence of travel and recent admission to hospitals in India or Pakistan.

The researchers identified 44 isolates with NDM-1 in Chennai, 26 in Haryana, 37 in the UK, and 73 in other sites in India and Pakistan. NDM-1 was mostly found between E. coli (36) and Klebsiella pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin. Most of the isolates carried the NDM-1 gene on plasmids: those from UK and Chennai were readily transferable from one bacterium to the other, whereas those from Haryana were not conjugative. Many of the UK NDM-1 positive patients had travelled to India or Pakistan within the past year, or had links with these countries. The study was published in the August 10, 2010, issue of Lancet Infectious Diseases.

"In many ways, this is it,” said coauthor Professor Tim Walsh, Ph.D., of the department of infection, immunity, and biochemistry at Cardiff University, in an interview published in the Guardian "This is potentially the end. There are no antibiotics in the pipeline that have activity against NDM 1-producing Enterobacteriaceae. We have a bleak window of maybe 10 years, where we are going to have to use the antibiotics we have very wisely, but also grapple with the reality that we have nothing to treat these infections with.”

"A lot of modern medicine would become impossible if we lost our ability to treat infections. The emergence of antibiotic resistance is the most eloquent example of Darwin's principle of evolution that there ever was,” added coauthor Professor David Livermore, Ph.D., of the UK Health Protection Agency (HPA; London). "It is a war of attrition. It is naive to think we can win.”

Beta-lactamases are enzymes produced by some bacteria responsible for their resistance to beta-lactam antibiotics like penicillins, cephamycins, and carbapenems. These antibiotics have a common element in their molecular structure: a four-atom ring known as a beta-lactam. The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties.

Related Links:
University of Madras
Cardiff University
UK National Reference Laboratory
UK Health Protection Agency



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.